G蛋白亲和色谱法纯化动物血清、抗体效果比较

比较 Hitrap G蛋白 Sepharose亲和色谱系统对不同动物血清或腹水的纯化效果 ,为抗体纯化提供依据。结果显示 ,G蛋白对不同动物血清 Ig G吸附能力不同 ,体现在单位体积抗体回收量明显不同 ,这一特点与 A蛋白亲和色谱系统相似。该方法简便快速 ,纯化抗体纯度高 ,免疫活性好 ,色谱柱可反复使用多次     

A蛋白亲和层析法纯化动物血清抗体的效果比较

用ＨｉｔｒａｐＰｒｏｔｅｉｎ－ＡＳｅｐｈａｒｏｓｅ亲和层析系统,对不同动物血清或抗血清抗体的纯化效率进行了比较,为选择抗体纯化方法提供依据。该方法简便快速,纯化的抗体纯度高,能较好地保持抗体免疫学活性。层析柱反复使用４０多次,纯化抗体效率不变。但Ｐｒｏｔｅｉｎ－Ａ对不同动物血清的ＩｇＧ吸附能力不同：对兔和豚鼠的血清抗体吸附能力强     

免疫磁珠技术分离唾液A/B血型抗原并用于吸附血清A/B抗体

目的:应用免疫磁珠分离技术获得具有良好抗原性的A/B血型抗原,并探究其作为ABO血型抗体吸附剂去除A/B抗体的可行性。方法:将含有血型物质的唾液进行预处理,再与包被了抗体的磁珠混合,分离出纯度较高的A/B抗原,运用酶联免疫及凝集抑制试验验证所得抗原的抗原性及是否存在交叉反应。用未纯化A/B抗原和纯化A/B抗原包被磁珠,对含有抗A/B IgM、IgG的血清进行抗体吸附,用纯化A/B抗原对100份来自O型血孕妇的临床血清样本进行抗体吸附,分别评价其吸附效果。结果:纯化抗原与对应抗体反应后,其吸光度显著高于对照组(A抗原与A抗体0.85±0.12 vs.0.27±0.03,P0.01;B抗原与B抗体0.86±0.09 vs.0.24±0.06,P0.01),与其它类型抗体反应后的吸光度值与对照组比较差异无统计学意义(P0.05)。进行红细胞凝集抑制试验时,纯化抗原可显著抑制相应抗体与红细胞的凝集反应,对其它类型抗体与红细胞的凝集没有抑制作用。血清抗体吸附实验表明纯化抗原的吸附效率比未纯化抗原的高(97.00%vs.88.00%,P0.001)。临床样本抗体吸附实验显示,纯化A抗原对抗A IgM/IgG的吸附效率分别为96.88%、98.44%;纯化B抗原对抗B IgM/IgG的吸附效率分别为96.88%、98.44%。结论:磁珠纯化抗原能特异性地与对应抗体结合,有效吸附血清中的血型抗体,有望作为合成A/B抗原的替代品。     

重组酶Exo的纯化及多克隆抗体制备

目的:纯化Exo重组酶融合蛋白并制备相应抗体。方法:用阴离子交换柱对蛋白进行初步纯化,然后用Ni-NTA介质填充的层析柱分离纯化含His标签的融合蛋白,用谷胱甘肽琼脂糖4B介质填充的层析柱分离纯化GST融合蛋白;二次纯化的蛋白利用硝酸纤维素膜结合法制备抗原蛋白并免疫实验动物。结果:ELISA结果显示血清抗体效价可达到1∶12 800,说明通过Western免疫印迹自制的多克隆抗体能特异地与Exo重组蛋白相互作用。结论:该蛋白纯化方法操作简单,制备的抗原纯度高,多克隆抗体特异性好。     

SARS-CoV-2受体结合域蛋白的表达、纯化和鉴定

目的实现严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)受体结合域(receptor-binding domain, RBD)蛋白的高效分泌表达,获得纯度较高的目的蛋白,并对目的蛋白与不同抗体的结合活性进行比较分析。方法将SARS-CoV-2 S蛋白RBD和RBD-Mouse IgG2a Fc基因优化合成后分别克隆入pcDNA3.1(+)或者pLexm表达载体,然后将获得的重组质粒转染HEK293F细胞,比较不同表达载体及添加标签对目的蛋白表达量的影响,选取表达量高的重组质粒进行后续转染,收获细胞上清后进行蛋白纯化。纯化后的蛋白分别与灭活SARS-CoV-2免疫马血清、CR3022抗体进行反应,比较RBD蛋白与不同抗体的结合活性。结果成功构建含SARS-CoV-2 RBD序列的不同重组表达质粒,表达结果显示,与其他质粒相比,RBD-mg2afc/pcDNA3.1(+)在细胞上清中获得较高水平的表达。纯化后的RBD蛋白纯度大于95%,Western blot检测结果显示,加热变性后的目的蛋白可以与灭活SARS-CoV-2免疫马血清发生特异性反应,但是与CR3022抗体几乎不发生反应;ELISA检测结果表明,纯化后的RBD蛋白可以与2种抗体均发生特异性反应,当抗原包被量低于500 ng/孔时,RBD蛋白与灭活SARS-CoV-2免疫马血清的结合能力高于其与CR3022抗体的结合能力,当抗原包被量高于500 ng/孔时,RBD蛋白与CR3022抗体的结合能力更强。结论成功表达和纯化了RBD蛋白,该蛋白在不同包被抗原量条件下与抗体的结合活性不同。     

貉血清IgG纯化及抗血清的制备

目的 制备高纯度貉血清IgG和兔抗貉IgG抗血清,作为建立多种动物抗体检测技术的储备。方法 采用Hitrap Protein A亲和层析及盐析再沉淀法纯化貉血清IgG,通过PAGE电泳和Western-Blot免疫印迹法对IgG作纯度及免疫活性检测;常规免疫法制备兔抗貉IgG血清。结果 貉血清IgG与Protein G虽有较强的结合力,但同时也结合血清中其他杂蛋白;用二步纯化法可从5 mL貉血清中纯化IgG约7 mg,电泳和免疫印迹测定显示,IgG纯度大于95%,常规免疫法制备抗血清免疫双扩散效价达1∶32。结论 建立了可行的貉血清IgG的纯化方法和高效价的兔抗貉血清IgG抗血清,为貉血清IgG二级抗体酶联物的制备储备了资源。     

影响PVDF膜对蛋白吸附效率的主要因素

通过结合有抗原的PVDF膜进行亲和纯化是小规模快速获取特异性抗体的一种重要手段.该方法的关键步骤之一是将抗原蛋白有效地吸附到PVDF膜上.尽管人们广泛使用PVDF膜亲和纯化抗体,但对影响PVDF膜吸附抗原蛋白的因素至今仍缺乏系统研究.以BSA为模型蛋白,检测在不同蛋白浓度、不同孵育时间、不同溶质溶液和不同pH值的情况下,PVDF膜吸附蛋白的效率.当蛋白溶液为PBS时,1 cm2 PVDF膜与2 mg·mLl BSA溶液孵育1h可达到其最大吸附率.常见的蛋白质缓冲液组分对PVDF膜的蛋白吸附率影响不一.其中,咪唑、Tris-HCl、NaCl、KCl在广泛的浓度范围内对PVDF膜吸附蛋白没有明显影响,而较高浓度的SDS、Triton-X 100、Tween-20、乙二醇、甘油、盐酸胍、尿素等可显著降低PVDF膜对蛋白的吸附效率,在pH为6.5～9.5的Tris-HCl中,随着pH的增高而吸附效率降低.     

虎血清免疫球蛋白（IgG）的纯化及纯度、活性鉴定

目的 建立高纯度、高活性的虎血清IgG纯化方法。方法 用饱和硫酸铵沉淀虎血清得到IgG粗品;结合Hitrap Protein A亲和层析预装柱及阴离子交换层析法对粗品IgG进一步分离纯化,采用PAGE电泳和Western-Blot免疫印迹法鉴定IgG纯度和免疫活性。结果 80 mL虎血清亲和纯化得到84 mg IgG,阴离子交换层析纯化得到30 mg虎的IgG纯品。结论 建立了简便快速、纯度高、活性好的虎血清IgG的分离纯化方法,为虎血清IgG二级抗体的制备提供了高纯度、活性好的一级抗体免疫原。     

MDCK细胞宿主蛋白含量双抗体夹心ELISA检测方法的建立

目的建立检测犬肾细胞(madin-darby canine kidney, MDCK)宿主细胞蛋白(host cell protein, HCP)含量的双抗体夹心ELISA。方法从MDCK细胞中提取细胞总蛋白,免疫新西兰兔制备兔抗MDCK细胞蛋白多克隆抗体,抗体经辛酸-硫酸铵沉淀和Protein A层析纯化后,采用SDS-PAGE分析抗体纯度,Western blot检测抗体特异性。用纯化的多克隆抗体作为包被抗体,并采用改良过碘酸钠标记法制备酶标抗体,建立ELISA并确定包被抗体浓度和辣根过氧化物酶(HRP)标记抗体稀释度等最适条件。确定该方法较佳的线性范围及检测限,并对该法特异性、准确度、精密性和重复性进行验证。最后,用该方法分别对接种流感病毒的MDCK细胞上清收获液和纯化样品进行MDCK细胞蛋白含量检测,初步验证其在纯化工艺开发中的适用性。结果通过免疫新西兰兔制备了高滴度的兔抗MDCK细胞蛋白多克隆抗体血清,滴度可达1∶8 000。纯化后的兔抗MDCK细胞蛋白多克隆抗体纯度>90%,并可与MDCK细胞蛋白特异性结合。建立的双抗体夹心ELISA的理想包被抗体质量浓度为10μg/mL,酶标抗体的工作浓度为1∶500稀释。该方法的线性范围为50~2 500 ng/mL,检测限为50 ng/mL;该方法对Vero细胞、293T细胞和Mrc-5细胞等其他细胞HCP无交叉反应,特异性良好;不同浓度的MDCK细胞HCP回收率在98.5%~111.9%之间,变异系数均<10%。接种流感病毒的MDCK细胞培养上清经多步纯化后MDCK细胞蛋白质量浓度逐渐降低至<900 ng/mL,纯化工艺可有效去除MDCK细胞蛋白残留。结论建立双抗体夹心ELISA检测MDCK细胞残余HCP含量的方法,可用于基于MDCK细胞培养的流感疫苗下游工艺开发中宿主细胞残留HCP含量监测。     

两种果子狸血清IgG纯化方法 的比较

目的 探讨一种具有简便快捷、高纯度、活性好的果子狸血清IgG纯化方法。方法 比较Hitrap Protein A亲和层析和PAGE电泳两种纯化法对果子狸血清IgG的纯化,用PAGE还原电泳和Western-Blot法对IgG作纯度鉴定。结果 对Hitrap Protein A纯化的果子狸血清IgG,其活性虽好,但纯度不高;而非还原PAGE电泳所纯化的果子狸血清IgG不但纯度高（〉95%）、并具有较强的免疫活性。结论 非还原PAGE电泳法纯化果子狸血清IgG,是一种具有高纯度、免疫活性强的纯化方法 。     

长爪沙鼠IgG的纯化及抗血清的制备

目的 纯化长爪沙鼠血清IgG,制备兔抗长爪沙鼠IgG抗血清。方法 采用Hitrap Protein G亲和层析预装柱来纯化长爪沙鼠血清IgG;通过SDS-PAGE电泳和Western-Blotting免疫印迹法对长爪沙鼠血清IgG进行纯度鉴定,免疫兔子制备抗血清。结果 7 mL长爪沙鼠血清纯化得到11 mg IgG;电泳和免疫印迹测定,IgG纯度大于95%;用纯化的IgG作抗原制备了兔抗血清,免疫双扩散测定效价达1∶32。结论 建立了长爪沙鼠血清IgG的纯化方法,制备了长爪沙鼠IgG抗血清,证实长爪沙鼠血清IgG和Protein G具有较高的亲和性。     

蝙蝠血清IgG的纯化及兔抗蝙蝠IgG酶标抗体的制备

目的纯化蝙蝠血清IgG,制备兔抗蝙蝠IgG酶标抗体。方法采用亲和层析纯化法纯化蝙蝠血清IgG,SDS-PAGE电泳鉴定蝙蝠IgG纯度。免疫大白兔制备兔抗蝙蝠IgG抗血清,免疫双扩散法测定抗血清效价,亲和层析纯化法纯化抗血清IgG。用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,直接ELISA和Western blot法对兔抗蝙蝠IgG酶标抗体进行工作浓度测定。结果纯化的蝙蝠血清IgG,其SDS-PAGE测定纯度大于95%;免疫大白兔所制备的抗血清免疫双扩散效价为1∶64;用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,其直接ELISA和Western blot工作浓度分别为1∶12800和大于1∶2000。结论制备了蝙蝠血清IgG的抗血清和酶标抗体,为蝙蝠的血清学检测体系提供了技术和资源储备。     

黑线毛足鼠和金仓鼠血清IgG的纯化及抗血清的制备

目的 纯化黑线毛足鼠和金仓鼠血清IgG,制备兔抗金仓鼠和黑线毛足鼠血清IgG的抗血清。方法 用Hitrap Protein G亲和层析纯化黑线毛足鼠和金仓鼠血清IgG,经SDS-PAGE电泳鉴定纯度,标准免疫方法免疫兔子制备抗血清。结果 黑线毛足鼠和金仓鼠血清IgG对protein G有很高的亲合性,用Hitrap Protein G亲和层析纯化,得到高纯度黑线毛足鼠和金仓鼠IgG,利用纯化的IgG作抗原制备了高效价的抗血清,免疫双扩散测定效价达1∶32和1∶16。结论 证实黑线毛足鼠和金仓鼠IgG和Protein G具有很高的亲和性,Protein G亲和层析是纯化黑线毛足鼠和金仓鼠IgG有效的方法之一,制备了黑线毛足鼠和金仓鼠IgG的抗血清。     

IgG PURIFICATION USING AFFINITY FILTRATION WITH SULFAMETHAZINE-AFFINITY CARRIERS

Immunoglobulin G (IgG) antibodies are used extensively for analytical, diagnostic, and therapeutic applications. However, there are some disadvantages to purify IgG antibodies by protein A and G affinity chromatography. Therefore, it is necessary to find an effective alternative and nonchromatographic method to purify IgG. Dextran microparticles were activated and coupled with sulfamethazine to form sulfamethazine-affinity carriers. Then the carriers were used to purify IgG by affinity filtration. Quantitative and qualitative determination proved that sulfamethazine would successfully bond to the surface of dextran microparticles with a density of 85.5 μmol/g (wet). Affinity carriers were proved to withstand high shear force and reveal rare sulfamethazine leakage under filtration conditions between pH 3 to 11. The maximum IgG-binding capacity of affinity carriers was 8.03 mg IgG/g (wet). The affinity filtration process obtained a recovery yield above 80% and purity above 90%. Thus, this work involved in both the advantages of membrane filtration and affinity purification. The results, for the first time, proved that it is possible to use the small ligand sulfamethazine for affinity filtration of IgG. It is an attractive alternative to conventional protein A or G affinity chromatography.     

Affinity purification of immunoglobulin M using a novel synthetic ligand

While monoclonal antibodies of the G class can be conveniently purified by affinity chromatography using immobilized protein A or G, even on a large scale, scaling up IgM purification still presents several problems, since specific and cost-effective ligands for IgM are not available. A synthetic peptide (TG19318), deduced from the screening of a combinatorial peptide library, was characterized previously by our group for its binding properties for immunoglobulins of the G class and its applicability as a synthetic ligand for polyclonal and monoclonal IgG purification, from sera or cell culture supernatants. In this study, we have examined the ligand recognition properties for IgM, immobilizing the synthetic peptide on different affinity supports and examining its ability to purify IgMs from serum, ascitic fluid and cell culture supernatants. TG19318 affinity columns proved useful for a very convenient one-step purification of monoclonal IgMs directly from crude sources, loading the samples on the columns equilibrated with saline buffers at pH values ranging from 5 to 7, and eluting adsorbed IgM by a buffer change to 0.1 M acetic acid or 0.05–0.1 M sodium bicarbonate, pH 9.0. Antibody purity after affinity purification was very high, close to 85–95%, as determined by densitometric scanning of sodium dodecyl sulfate–polyacrylamide gels of purified fractions, and by gel permeation analysis. Antibody activity was fully recovered after purification, as determined by immunoassays. Column capacity was related to the type of support used for ligand immobilization, and ranged from 2 to 8 mg of IgM/ml of support.     

Analysis and isolation of human transferrin receptor using the OKT-9 monoclonal antibody covalently crosslinked to magnetic beads.

A method is described for the use of magnetic beads as a solid phase for the immunoprecipitation of labeled proteins. The anti-human transferrin receptor monoclonal antibody OKT-9 has been coupled to sheep anti-mouse IgG1-coated magnetic beads using the crosslinking agent dimethyl pimelimidate. The transferrin receptor is readily detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography following immunoprecipitation from 35S-labeled cell lysates. When compared with precipitations using OKT-9 coupled to protein G Sepharose the magnetic beads result in fewer nonspecific bands. The protocol described is generally applicable to the identification of labeled proteins. In addition, because magnetic beads are amenable to covalent crosslinking procedures they can be used for the purification of proteins from complex mixtures. Covalently crosslinked OKT-9 sheep anti-mouse IgG1-coated magnetic beads have been used to affinity purify unlabeled transferrin receptor from cell lysates giving comparable purity and yield to transferrin Sepharose isolated transferrin receptor. The major advantages offered by magnetic beads compared to conventional affinity matrices are low nonspecific binding and the rapidity with which the purification can be performed.